Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
暂无分享,去创建一个
Jean-Michel Rondeau | Laura Jacobson | M. Staufenbiel | J. Rondeau | S. Desrayaud | H. Möbitz | L. Jacobson | U. Neumann | Matthias Staufenbiel | Ulf Neumann | H. Rueeger | R. Lueoend | O. Rogel | R. Machauer | Sandrine Desrayaud | Rainer Machauer | Heinrich Rueeger | Rainer Lueoend | Olivier Rogel | Henrik Möbitz | Henrik Möbitz
[1] M. Malamas,et al. Acylguanidine inhibitors of β-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets , 2008 .
[2] Migliore Amico. Ensemble-docking approach on BACE-1 : Pharmacophore Perception and Guidelines for Drug Design , .
[3] Li Di,et al. Strategies to assess blood–brain barrier penetration , 2008, Expert opinion on drug discovery.
[4] John-Michael Sauer,et al. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. , 2009, Bioorganic & medicinal chemistry letters.
[5] Brian Clarke,et al. Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. , 2008, Journal of medicinal chemistry.
[6] S. Stachel. Progress toward the development of a viable BACE‐1 inhibitor , 2009 .
[7] Rutger H A Folmer,et al. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. , 2007, Journal of medicinal chemistry.
[8] Shumeye Mamo,et al. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. , 2007, Journal of medicinal chemistry.
[9] P. Saftig,et al. Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.
[10] N. Blomberg,et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.
[11] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[12] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[13] A. Simon,et al. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. , 2008, The Journal of pharmacology and experimental therapeutics.
[14] Qi Zhang,et al. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. , 2008, Bioorganic & medicinal chemistry letters.
[15] H. Cai,et al. BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.
[16] D. E. Clark,et al. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.
[17] R. Doms,et al. Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. , 2002, Biochemistry.
[18] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[19] A. Simon,et al. In Vivo β-Secretase 1 Inhibition Leads to Brain Aβ Lowering and Increased α-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[20] M. Malamas,et al. Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability. , 2010, Bioorganic & medicinal chemistry letters.
[21] Matthew S. Johnson,et al. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. , 2009, Journal of medicinal chemistry.
[22] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[23] Manuel Buttini,et al. Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.
[24] C. Dingwall,et al. Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics. , 2009, Bioorganic & medicinal chemistry letters.
[25] Amy S. Espeseth,et al. Design and Synthesis of 2,3,5‐Substituted Imidazolidin‐4‐one Inhibitors of BACE‐1 , 2007, ChemMedChem.
[26] W. Pardridge,et al. Blood-brain barrier delivery. , 2007, Drug discovery today.
[27] P. Verhoest,et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.
[28] Rajiv Chopra,et al. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. , 2010, Journal of medicinal chemistry.
[29] J. Buxbaum,et al. BACE (β-secretase) modulates the processing of APLP2 in vivo , 2004, Molecular and Cellular Neuroscience.
[30] A. Vulpetti,et al. Fluorine–Protein Interactions and 19F NMR Isotropic Chemical Shifts: An Empirical Correlation with Implications for Drug Design , 2011, ChemMedChem.
[31] R. Doms,et al. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. , 2000, The Journal of biological chemistry.
[32] Christopher G. Wilson,et al. BACE1 Deficiency Causes Altered Neuronal Activity and Neurodegeneration , 2010, The Journal of Neuroscience.
[33] M. Malamas,et al. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket. , 2008, Bioorganic & medicinal chemistry letters.
[34] Joachim Kraemer,et al. Fragment-based discovery and optimization of BACE1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[35] Remigijus Didziapetris,et al. Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.
[36] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[37] W. Richards,et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.
[38] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.
[39] I. Hidalgo,et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.
[40] K. Roth,et al. Cathepsin D Deficiency and NCL/Batten Disease: There’s More to Death than Apoptosis , 2007, Autophagy.
[41] Yuan Cheng,et al. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.
[42] A. Seelig. A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.
[43] J. Macor,et al. Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1. , 2011, Bioorganic & medicinal chemistry letters.
[44] Alison R. Gregro,et al. Evolution of Tertiary Carbinamine BACE‐1 Inhibitors: Aβ Reduction in Rhesus CSF upon Oral Dosing , 2009, ChemMedChem.
[45] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[46] Alison R. Gregro,et al. Discovery of Isonicotinamide Derived β-Secretase Inhibitors: In Vivo Reduction of β-Amyloid , 2007 .
[47] T. Hirai,et al. Trifluoropropene oxide as a trifluoromethyl source. Preparation of optically active alcohols , 1990 .
[48] Rudi D'Hooge,et al. Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.
[49] U. Norinder,et al. Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.
[50] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[51] D. Riddell,et al. BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character. , 2008, Bioorganic & medicinal chemistry letters.
[52] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[53] B. Trapp,et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] Alison R. Gregro,et al. First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.
[55] G. Tóth,et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. , 2010, Bioorganic & medicinal chemistry letters.
[56] Alison R. Gregro,et al. Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid. , 2007, Journal of medicinal chemistry.
[57] C. Southan,et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. , 1999, Molecular and cellular neurosciences.
[58] B. de Strooper,et al. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing , 2011, Journal of neurochemistry.
[59] M. Citron. Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.
[60] R. Motter,et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. , 2010, Bioorganic & medicinal chemistry letters.
[61] Gabriele Cruciani,et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. , 2005, Journal of medicinal chemistry.
[62] Clive McCarthy,et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[63] Junya Qu,et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. , 2007, Journal of medicinal chemistry.
[64] Gianni Chessari,et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.
[65] R. Doms,et al. Maturation and Endosomal Targeting of β-Site Amyloid Precursor Protein-cleaving Enzyme , 2000, The Journal of Biological Chemistry.
[66] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[67] Markus Kroemer,et al. APRV - a program for automated data processing, refinement and visualization. , 2004, Acta crystallographica. Section D, Biological crystallography.
[68] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[69] Gilles Klopman,et al. MultiCASE Expert Systems and the REACH Initiative , 2008, Toxicology mechanisms and methods.
[70] B. de Strooper,et al. Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β′-site increases Aβ generation† , 2011, EMBO molecular medicine.
[71] Romano Silvestri,et al. Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease , 2009, Medicinal research reviews.
[72] Stephen Hanessian,et al. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. , 2005, Journal of medicinal chemistry.
[73] J. Bunch,et al. Aryl trifluoromethyl acetylenes , 1987 .
[74] D. Hazuda,et al. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[75] Lingyan Wang,et al. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.
[76] H. Sham,et al. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. , 2010, Bioorganic & medicinal chemistry letters.
[77] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[78] Wolfgang Kabsch,et al. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .
[79] Colin McMartin,et al. QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..
[80] R. Doms,et al. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. , 2003, The Journal of biological chemistry.
[81] D. Riddell,et al. BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. , 2008, Bioorganic & medicinal chemistry letters.
[82] H. Cai,et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.
[83] P. Wong,et al. BACE1 Knock-Outs Display Deficits in Activity-Dependent Potentiation of Synaptic Transmission at Mossy Fiber to CA3 Synapses in the Hippocampus , 2008, The Journal of Neuroscience.
[84] H. Cai,et al. BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.
[85] David C Lankin,et al. Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[86] Dongwoo Shin,et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase). , 2000, Journal of the American Chemical Society.
[87] Michael Czarniecki,et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.
[88] R. Doms,et al. Secretion and Intracellular Generation of Truncated Aβ in β-Site Amyloid-β Precursor Protein-cleaving Enzyme Expressing Human Neurons* , 2003, The Journal of Biological Chemistry.
[89] Paul Zuck,et al. Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. , 2008, Journal of medicinal chemistry.
[90] R. Neve,et al. Age-Dependent Neuronal and Synaptic Degeneration in Mice Transgenic for the C Terminus of the Amyloid Precursor Protein , 1996, The Journal of Neuroscience.
[91] Joseph B. Moon,et al. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. , 2007, Journal of medicinal chemistry.
[92] Simone Braggio,et al. Assessing brain free fraction in early drug discovery , 2010, Expert opinion on drug metabolism & toxicology.
[93] S. Hitchcock,et al. Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.
[94] A. Stamford,et al. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[95] J. Tang,et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[96] J. Buxbaum,et al. BACE (beta-secretase) modulates the processing of APLP2 in vivo. , 2004, Molecular and cellular neurosciences.
[97] C. Dingwall,et al. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. , 2009, Bioorganic & medicinal chemistry letters.
[98] Y. Kiso,et al. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors , 2009, Expert opinion on drug discovery.
[99] A. Seelig,et al. Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[100] C. Dingwall,et al. Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent. , 2009, Bioorganic & medicinal chemistry letters.
[101] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[102] A. Good,et al. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE). , 2011, Bioorganic & medicinal chemistry letters.
[103] B. Platt,et al. Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. , 2008, Bioorganic & medicinal chemistry letters.
[104] D. Price,et al. Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System , 2011, The Journal of Neuroscience.
[105] G. Olah,et al. Novel Preparation of gem-Difluorides from Ketoximes with Nitrosonium Tetrafluoroborate and Pyridinium Polyhydrogen Fluoride 1 , 1994 .
[106] A. Aronov. Ligand structural aspects of hERG channel blockade. , 2008, Current topics in medicinal chemistry.
[107] P. Verhoest,et al. Strategies to optimize the brain availability of central nervous system drug candidates , 2011, Expert opinion on drug discovery.
[108] A. Stamford,et al. Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.